C2orf61 Inhibitors

Phosphoinositide 3-kinase (PI3K) inhibitors such as Wortmannin and LY294002 disrupt a fundamental cell signaling pathway, leading to alterations in cell survival, proliferation, and metabolism, which are processes that C2orf61 potentially influences. Mitogen-activated protein kinase (MAPK) inhibitors, including PD98059 and U0126, target enzymes responsible for conveying extracellular signals to the cell's interior, thus affecting cellular responses to growth factors and stress. This disruption can significantly change the signaling landscape where C2orf61 operates. Similarly, c-Jun N-terminal kinase (JNK) and p38 MAPK inhibitors like SP600125 and SB203580, respectively, modulate stress and inflammatory responses, which could indirectly influence the function of C2orf61.

Rapamycin, an inhibitor of the mechanistic target of rapamycin (mTOR), impacts a central hub in cell growth and metabolism, which could have a broad effect on cellular processes linked with C2orf61. Akt inhibitors, namely Triciribine, target a kinase involved in crucial cell survival pathways, potentially affecting the same milieu as C2orf61. Protein kinase C (PKC) inhibitors, such as Chelerythrine and Gö 6983, interfere with signaling pathways related to cell proliferation and apoptosis, which may also intersect with pathways involving C2orf61. Finally, NF-κB inhibitors like BAY 11-7082 affect the regulation of immune response and inflammation, which can have consequences for the broader network of signaling in which C2orf61 is implicated.